Antibodies Engineered to Deliver Treatments for Obesity and Cardiometabolic Disease
GLP-1s revolutionized obesity treatment but leave major gaps in patient care. That’s where we come in.
Obesity treatment gaps and the need for reliable options
Despite meaningful weight loss, GLP-1 therapies can be limited by muscle loss, gastrointestinal side effects, adherence challenges, and frequent weight regain after discontinuation. Our antibodies are designed to address these limitations.
Outcomes that matter to patients
Preserve muscle strength during weight loss
Current GLP-1 treatments often cause patients to lose muscle with the loss of fat, which can lead to an increased risk of fractures. Our candidates are designed to protect muscle mass during weight loss.
Target fat without suppressing appetite
The majority of currently available obesity treatments block feelings of hunger. We’re developing therapies targeting fat storage differently, so patients can lose weight and maintain normal appetite signals.
Reduce weight regain after treatment
Weight regain is a common frustration patients face after ending GLP-1 treatment. Our approach is designed to create lasting metabolic changes that help patients maintain weight loss over time, breaking the discouraging cycle of losing and regaining weight.
Less frequent doses
Daily pills or weekly injections requirements can become burdensome for patients. Our long-acting antibody candidates are designed to require less frequent administration.
Gentler on digestion
Gastrointestinal side effects like nausea and vomiting are common GLP-1 side effects. We aim to offer alternatives with fewer gastrointestinal disturbances.
Explore our pipeline
Our platform is the engine behind our pipeline, enabling rapid program advancement and consistently generating unique molecules with favorable developability profiles for obesity and cardiometabolic disease. Explore how our AI–wet-lab integration drives discovery and development across all programs.
our pipeline